公开(公告)号：US20220409679A1

公开(公告)日：2022-12-29

申请号：US17756570

申请日：2020-11-27

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： TINU MARY SAMUEL

IPC分类号： A61K35/747 ,  A61K31/015 ,  A61K31/375 ,  A61K31/519 ,  A61K31/51 ,  A61K31/525 ,  A61K31/197 ,  A61K31/4415 ,  A61K31/714 ,  A61K33/30 ,  A61K33/32 ,  A61K33/26 ,  A61K33/04 ,  A61K33/34 ,  A61K33/06 ,  A61K33/00 ,  A61K38/38 ,  A61K31/685 ,  A61K31/202 ,  A61K31/122 ,  A61P29/00

摘要： The invention provides a mix or a nutritional composition comprising a probiotic Lactobacillus Fermentum CECT-5716 and a nutrient selected from the group consisting of beta-carotene, fiber, Vitamin C, Folate, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12 and Potassium, or combination of two of more thereof, for use in treating or preventing mastitis, especially subclinical mastitis, in a subject, preferably a pregnant or lactating woman.

公开(公告)号：US20220409678A1

公开(公告)日：2022-12-29

申请号：US17638528

申请日：2020-11-19

申请人： JINIS CO., LTD

发明人： Hyeon Jin KIM ,  Sang Woo KIM ,  Seong Tshool HONG

IPC分类号： A61K35/747 ,  A61K35/744 ,  A61P25/28

摘要： Microorganisms for lowering blood ammonia level and composition for protecting neuronal cells containing the same, particularly relates to microbes or a symbiotic pair that has a neuroprotective function by lowering blood ammonia levels or reducing ammonia levels in the body and composition for protecting neuronal cells comprising the microbes. The microorganisms having a neuroprotective function by lowering the blood ammonia level can be selected from the group that include, but not limited to, a Lactobacillus sp. strain and a Streptococcus sp. strain. The ammonia removal strains and the composition have a neuroprotective effect by their excellent ability to remove neurotoxic ammonia, and thus can be widely used as a preventive or therapeutic agent for hyperammonemia and neurological diseases caused thereby.

公开(公告)号：US11534468B2

公开(公告)日：2022-12-27

申请号：US16770011

申请日：2018-12-06

申请人： LAC2BIOME S.R.L.

发明人： Andrea Biffi

IPC分类号： A61K35/747 ,  A61P17/02 ,  A61K8/99 ,  A61K35/745 ,  A61K35/00 ,  A61Q17/00 ,  A61Q17/04 ,  A61Q19/08

摘要： The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

公开(公告)号：US11530414B2

公开(公告)日：2022-12-20

申请号：US16471872

申请日：2018-10-16

申请人： CELL BIOTECH CO., LTD.

发明人： Myung Jun Chung

IPC分类号： A61K35/747 ,  A61K35/744 ,  A61K35/745 ,  A61K35/00 ,  C12N15/74 ,  C12N15/65 ,  C12R1/23 ,  C12R1/24 ,  C12R1/245

摘要： The present invention relates to a gene expression cassette including a strong promoter derived from lactic acid bacteria, and a gene expression vector including the same. According to the present invention, a large amount of a human protein, the physiological activity of which has been verified, may be stably produced with high efficiency by introducing a useful foreign gene into an expression vector and transforming probiotics with the expression vector. Through the production of this protein, it is possible to provide a basis for developing functional probiotics and making products using them.

公开(公告)号：US11529382B2

公开(公告)日：2022-12-20

申请号：US16938358

申请日：2020-07-24

申请人： Syngen Biotech. Co., Ltd.

发明人： Wei-Jen Chen ,  Shiuan-Huei Wu ,  Chiau-Ling Gung ,  Yu-Lun Tsai

IPC分类号： A61K35/747 ,  C12N1/20 ,  A61P29/00 ,  A61P35/00 ,  C12R1/225

摘要： The present invention provides a novel Lactobacillus fermentum strain, named Lactobacillus fermentum strain V3, and its use in manufacturing a pharmaceutical composition or a food composition for regulating intestinal microflora and treating and/or preventing an inflammatory diseases and/or a cancer.

公开(公告)号：US11517596B2

公开(公告)日：2022-12-06

申请号：US17037173

申请日：2020-09-29

申请人： CHAMBIO CO., LTD.

发明人： Meei-Yn Lin ,  Hung-Pin Chiu ,  Yi-Heng Chiu

IPC分类号： A61K35/747 ,  A61K35/745 ,  A61K39/09 ,  A61K39/05 ,  A61P19/02 ,  A61K47/36 ,  A61K47/42 ,  A61K35/00

摘要： A method for alleviating arthritis includes administering to a subject in need thereof a postbiotic extract. The postbiotic extract is prepared by a process including the steps of providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to forma mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract.

公开(公告)号：US20220370525A1

公开(公告)日：2022-11-24

申请号：US17811542

申请日：2022-07-08

申请人： IMMUNOBIOME INC.

发明人： Sin-Hyeog IM ,  Garima SHARMA ,  Sun-Hee PARK ,  Amit SHARMA

IPC分类号： A61K35/747 ,  C12N1/20 ,  A23L33/135 ,  A61P35/00

摘要： The present invention relates to a novel Lactobacillus plantarum IMB19 strain, polysaccharides derived from the strain, and a use thereof. A novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent CD8+T cell activity stimulating ability and Treg cell inhibitory activity, and stimulate and improve an antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Therefore, a strain and polysaccharides derived from the strain of the present invention can be effectively used for immune regulation, especially immune boosting, in a subject, and can inhibit tumor growth by inducing and enhancing an antitumor immune response. A novel strain and polysaccharides derived from the strain of the present invention are useful in the prevention, alleviation or treatment of such as tumors, infectious diseases and various immune diseases that are the cause of or symptom of immune dysfunction.

公开(公告)号：US20220370524A1

公开(公告)日：2022-11-24

申请号：US17736387

申请日：2022-05-04

申请人： I EATING LIGHT LTD.

发明人： Hsin-Hua CHIANG ,  Bo-Jyun LIOU

IPC分类号： A61K35/747 ,  A23L33/00 ,  A23L33/135

摘要： Disclosed herein is an isolated strain of Lactobacillus acidophilus TW01, which is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33990. Also disclosed herein are use of the isolated strain of Lactobacillus acidophilus TW01 for alleviating an inflammation-related disorder and that for improving gut health.

公开(公告)号：US20220370522A1

公开(公告)日：2022-11-24

申请号：US17606977

申请日：2021-06-30

申请人： SYNBIO TECH INC.

发明人： San-Land YOUNG ,  Hau-Yang TSEN ,  Chen-Ying HUNG ,  Yu-Cheng CHIANG

IPC分类号： A61K35/747 ,  C12N1/20 ,  A61K35/745

摘要： Disclosed herein is an isolated strain of Lactobacillus amylovorus LAM1345, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33510. Also disclosed herein are a composition including the isolated strain of Lactobacillus amylovorus LAM1345 for reducing trimethylamine (TMA) and/or trimethylamine-n-oxide (TMAO) levels, and use of the isolated strain of Lactobacillus amylovorus LAM1345 for treating a disease associated with at least an elevated one of TMA and TMAO levels in a subject.

公开(公告)号：US20220362311A1

公开(公告)日：2022-11-17

申请号：US17621121

申请日：2020-06-19

申请人： Synlogic Operating Company, Inc. ,  Ginkgo Bioworks, Inc.

发明人： Ning Li ,  Jian-Rong Gao ,  Philippa Jane Reeder Morrison ,  Christopher George Bergeron ,  Dylan Alexander Carlin ,  Laura K. Stone ,  Alex C. Tucker ,  Patrick M. Boyle

IPC分类号： A61K35/747 ,  A61K35/741 ,  A61K35/745 ,  A61K35/742 ,  A61K35/744 ,  A61P13/02 ,  C12N1/20 ,  C12N15/52 ,  C12N15/70

摘要： The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patients internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding an improved leucine catabolism enzyme with higher activity and/or specificity for leucine over other branched chain amino acids, such as isoleucine or valine. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of leucine, isoleucine, and/or valine using the pharmaceutical compositions disclosed herein.